Extracellular Vesicle Loading with Cyclic Dinucleotides via Multimodal Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Systemic delivery of STING agonists for cancer treatment is limited by broad expression profile and systemic inflammation, leading to reduced therapeutic efficacy, and existing methods for intra-tumoral delivery are limited to solid tumors and cause tissue damage.
Innovation Solution
Development of a method to prepare extracellular vesicles (EVs) loaded with cyclic dinucleotides (CDNs) using a multimodal chromatography process to separate and purify EVs, enhancing their potency and stability, allowing for effective delivery of STING agonists directly to tumors while minimizing systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If systemic delivery of STING agonists is used, then broad immune activation is achieved, but systemic inflammation occurs reducing therapeutic efficacy
Solution Approach 1:
The patent employs targeted delivery of STING agonists to specific tumor sites rather than systemic distribution. EVs are engineered with tumor-targeting capabilities through surface modification with tumor-specific ligands, enabling localized immune activation at the tumor microenvironment while sparing other tissues from inflammatory effects
Solution Approach 2:
Extracellular vesicles serve as intermediary carriers to transport STING agonists from systemic circulation to tumor sites. The EVs protect the agonists during circulation and facilitate their selective accumulation at tumors through enhanced permeability and retention effect, as well as active targeting mechanisms
2Reliability
If intra-tumoral injection of STING agonists is used, then effective tumor treatment is achieved, but tissue damage occurs
Solution Approach 1:
The patent replaces mechanical injection methods with biologically-mediated delivery using extracellular vesicles. Instead of direct needle injection that causes physical tissue disruption, the system uses EVs that naturally circulate and accumulate at tumors, delivering the therapeutic agent without mechanical trauma
Solution Approach 2:
EVs act as intermediaries between the STING agonist and tumor cells, enabling gentle, non-invasive delivery. The vesicles protect the agonist during transport and enable controlled release at the target site through biological mechanisms rather than mechanical force
3Quantity of substance
If free CDNs are present in the composition, then loading concentration is achieved, but potency is reduced due to lack of specificity
Solution Approach 1:
The patent employs purification methods to extract and remove unbound free CDNs from the composition after EV loading. This separation ensures that only EV-associated CDNs remain in the final formulation, eliminating the dilution effect and off-target effects of free CDN while maintaining high local concentration at the tumor site
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly increases the potency and stability of STING agonists associated with EVs, enabling effective immune activation against tumors with reduced systemic inflammation and tissue damage, improving therapeutic efficacy and safety.
Implementation Method 1
the free CDNs are removed by a multimodal chromatography
Data Source
AI summary
Provided herein are methods of preparing EVs, e.g., exosomes, associated with or encapsulated various cyclic dinucleotides, including STING agonists. Also provided herein are methods of loading EVs, e.g., exosomes, with various cyclic dinucleotides, including STING agonists.